Linkoping

• REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting
  2022-502184-38-00 4 2025-06-06 Rapidly progressive glomerulonephritis
• RECURrence of Atrial Fibrillation after cardioversion of patients randomized to open-label treatment with dapagliflozin or usual care (RECUR … Recruiting
  2024-513719-28-00 11 2025-06-04 Atrial fibrillation
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• RandomizEd compariSOn of apixaban versus warfarin in patients with Left VEntricular thrombus after Acute Myocardial Infarction (RESOLVE-AMI) … Recruiting
  2024-514416-28-00 6 2025-04-09 Left ventricular thrombosis.
• The dual orexin receptor antagonist daridorexant as an adjunct to improve buprenorphine maintenance therapy of opioid use disorder Recruiting
  2024-517482-16-00 4 2025-04-04 Opioid Use Disorder [OUD]
• Vaccination against human papillomavirus (HPV) after allogeneic stem cell transplantation, a randomized study between early and late vaccina … Recruiting
  2022-502912-35-00 4 2025-03-12 Recipients of allogeneic stem cell transplantation
• Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl … Recruiting
  2023-506998-35-00 5 2025-01-08 Glioblastoma
• Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial ( … Recruiting
  2023-508398-10-00 6 2024-12-12 ANCA-associated vasculitis
• Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden Recruiting
  2024-518857-41-00 6 2024-11-29 HPV infection and related diseases, such as cervical intraepithelial n
• Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting
  2023-509994-22-00 5 2024-11-15 cutaneous malignant melanoma
• VEX-AZA: Treating VEXAS Syndrome with Azacitidine. A Single-Arm, Multicenter Phase II Study on the Efficacy and Safety of Azacitidine in Pat … Recruiting
  2024-510715-30-00 4 2024-09-26 VEXAS
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• Improved Recovery by Iron following Surgery with blood loss, a double-blind multi-centre randomized controlled phase III drug trial (the IRI … Recruiting
  2022-502776-22-00 5 2024-09-05 Anemia
• SGLT2 inhibitor or metformin as standard treatment in early type 2 diabetes (SMARTEST) Recruiting
  2024-516228-33-00 6 2024-08-30 Type 2 Diabetes
• A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared … Recruiting
  2023-508156-20-00 5 2024-06-10 Uveal Melanoma Liver Metastases
• Can estimated glomerular filtration rate (eGFR) predict which patients with S. aureus-bacteremia that will need adjusted dosing via therapeu … Recruiting
  2023-505148-20-00 6 2024-06-01 Staphyloccus aureus bacteremia
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• SMILe: Spinal Morphine or Intravenous Lidocaine in robot-assisted upper urologic surgery Recruiting
  2023-505941-21-00 5 2024-04-09 Renal or ureter malignancy; Renal or ureter benign tumor; Nephrolithia
• SGLT2 inhibitor TrEatment iN patients awaiting cOronary arTery bYpass surgery to reduce Post-opErative atrial fibrillation and kidney injury … Recruiting
  2023-505375-75-00 5 2024-04-04 Onset of Atrial Fibrillation and Acute Kidney Injury after coronary ar
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• Preeclampsia Intervention 4 Recruiting
  2022-502707-29-00 5 2024-02-07 Preeclampsia
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• Early Initiated Vasopressor Therapy in the Emergency Department - A Multi-center Randomized Controlled Trial (VASOSHOCK) Recruiting
  2023-504584-16-00 5 2023-12-08 Hypotension
• LiBRA – Lithium treatment to prevent cognitive impairment after brain radiotherapy. Recruiting
  2023-504071-24-00 4 2023-11-07 Brain tumor

Showing 49–72 of 174 trials